Neuroimaging
A 33-year-old, previously healthy woman began to show as lowly progressive short-term memory impairment affecting both verbal and non-verbal domains, with little subjective concern. She also had increasing difficulty with her retrograde memory, especially related to the months preceding the onset of illness. Three weeks later, she experienced her first generalised tonic-clonic convulsion. No obvious aetiology (including infection, recent vaccination, medication, drug abuse) was evident. Seizures in patients with brain tumours represent a frequent problem in clinical practice; in this setting, anticonvulsant treatment significantly reduces the rate of seizure generalisation, contributing to limitation of morbidity. Since inferior survival has been observed in subjects treated with enzyme-inducing anticonvulsants while receiving chemotherapy for acute leukaemia [1], there is an increasing tendency for prescription of non-enzyme-inducing AEDs for cancer patients. Although the most frequently used chemotherapy drugs for brain tumors like temozolomide or nitrosoureas (BCNU, CCNU, ACNU, fotemustine) are not significantly affected by CYP450 enzymes, salvage treatment includes agents like irinotecan, etoposide or tyrosine-kinase inhibitors (e.g., erlotinib, imatinib or cediranib), having an hepatic catabolism that may be enhanced by enzyme inductors.
A recent large retrospective US study on 620 patients with glioblastoma came to a surprising and counterintuitive conclusion, as acknowledged by the authors: after a careful statistical adjustment for prognostic factors such as age, performance status, extent of surgical resection, steroid use, and baseline neurocognitive function, overall and progression-free survival was higher in the 432 patients using enzyme-inducing antiepileptic drugs (AED) as compared to the 173 who did not [2] . However, several limitations prevent to draw any definitive conclusion from this observation [3, 4] . It is unclear what type of enzyme-inducing AED was used (given the study period, probably phenytoin and carbamazepine), but phenytoin bioavailability may be lowered by dexamethasone, which is frequently administered in this setting. Furthermore, it seems that several patients received AED as primary prophylaxis, but this does not correspond to current practice. Lack of data regarding longitudinal seizure history and tumour volume and location may also limit data interpretation.
Unfortunately, availableliterature comparing AED effectiveness in patients with brain tumours is extremely scarce. In glioma patients who had a previous seizure, a post-surgical switch from phenytoin to levetiracetam was addressed in arandomised phase II study. The trial closed early because of insufficient accrual after enrollment of 29 subjects. In the 23 patients with follow-up data at 6 months (15 on levetiracetam, 8 on phenytoin), seizure control was comparable, while side effects were less pronounced in the levetiracetam group [5] . Other recent studies on this topic are limited to patients series receiving a single compound, such as levetiracetam [6], pregabalin [7] , topiramate [8, 9] , zonisamide [10] , or oxcarbazepine [11] , and suggest that efficacy and tolerability seem reasonable. Intriguingly, lamotrigine is virtually not reported in this setting.
Awaiting prospectivec omparative studies it seems reasonable to prescribe AED devoid of pharmacological interactions in patients with brain tumours. In this context, levetiracetam and pregabalin have the advantage of a rapid titration, while lamotrigine needs several weeks to reach a therapeutic serum level. On the other side, topiramate, zonisamide, and oxcarbazepine have the theoretical disadvantage of exerting mixed (albeit modest) actions on the cytochrome system.
